These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 16118686)

  • 1. Metabolic Diseases World Summit 2005. 29 June-1 July 2005, San Francisco, CA, USA.
    James S
    IDrugs; 2005 Sep; 8(9):704-7. PubMed ID: 16118686
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic Diseases World Summit 2005. Partnering and deal-making. 29 June-1 July 2005, San Francisco, CA, USA.
    Clark AG
    IDrugs; 2005 Sep; 8(9):708-9. PubMed ID: 16118687
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes basics. Exenatide and pramlintide. New meds on the block.
    Griffin S; Borders J
    Diabetes Self Manag; 2006; 23(4):74-6, 79. PubMed ID: 16888865
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 5. First in class. Two new diabetes drugs.
    Koredella T
    Diabetes Forecast; 2005 Aug; 58(8):35-6. PubMed ID: 16124101
    [No Abstract]   [Full Text] [Related]  

  • 6. Type 2 diabetes drug boom: is newer better?
    Johns Hopkins Med Lett Health After 50; 2007 Aug; 19(6):3, 7. PubMed ID: 17712909
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic Diseases Drug Discovery World Summit--SRI conference. 28-29 July 2003 San Diego, CA, USA.
    Knittel T
    IDrugs; 2003 Sep; 6(9):845-9. PubMed ID: 14565169
    [No Abstract]   [Full Text] [Related]  

  • 8. USAN Council. List No. 419. New names. Pramlintide acetate.
    Clin Pharmacol Ther; 1999 Sep; 66(3):332. PubMed ID: 10576958
    [No Abstract]   [Full Text] [Related]  

  • 9. Bifunctional PEGylated exenatide-amylinomimetic hybrids to treat metabolic disorders: an example of long-acting dual hormonal therapeutics.
    Sun C; Trevaskis JL; Jodka CM; Neravetla S; Griffin P; Xu K; Wang Y; Parkes DG; Forood B; Ghosh SS
    J Med Chem; 2013 Nov; 56(22):9328-41. PubMed ID: 24144329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. Dipeptidyl peptidase-IV inhibitors 26-27 July 2004, San Diego, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):839-40. PubMed ID: 15470600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Diseases Drug Discovery-Strategic Research Institute's Third International World Summit. PPAR and PTB1B modulators 26-27 July 2004, San Diego, CA, USA.
    Xu J
    IDrugs; 2004 Sep; 7(9):836-8. PubMed ID: 15470599
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New peptide-based therapies for metabolic diseases.
    Culler MD
    Ann Endocrinol (Paris); 2008 Apr; 69(2):161. PubMed ID: 18420178
    [No Abstract]   [Full Text] [Related]  

  • 15. Application of incretin mimetics and dipeptidyl peptidase IV inhibitors in managing type 2 diabetes mellitus.
    Boyle PJ; Freeman JS
    J Am Osteopath Assoc; 2007 May; 107 Suppl():S10-6. PubMed ID: 17724013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. For parents. Type 1 diabetes research. Balancing hope with realism.
    Dinsmoor RS
    Diabetes Self Manag; 2003; 20(2):87-8, 91-2, 95, 99-102. PubMed ID: 12715738
    [No Abstract]   [Full Text] [Related]  

  • 17. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolic Diseases Drug Discovery World Summit.
    Liu G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):577-82. PubMed ID: 14662006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment of obesity.
    Bray GA; Ryan DH
    Psychiatr Clin North Am; 2011 Dec; 34(4):871-80. PubMed ID: 22098810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.